Tryp Therapeutics Inc.

CSE: TRYP

Company Overview

Tryp Therapeutics is a clinical stage drug development company led by a management team with extensive drug development experience that is advancing transformative medicines with existing clinical data and known safety profiles for diseases with no effective first-line treatments. The company is building a diversified portfolio of product candidates targeting neuropsychiatric and oncology indications with high unmet medical needs.

Financial Highlights

$0

Revenue (ttm)

$0

Gross Profit (ttm)

-$0.07

Diluted EPS (ttm)

Management Team

Dr. James P. Gilligan MSIB, Ph.D.
Interim CEO, Pres & Chief Scientific Officer

Dr. James S. Kuo M.B.A., M.D.
Co-Founder & Director

Mr. Jim O'Neill
Chief Financial Officer

Mr. Thomas D'Orazio B.Sc., M.B.A.
Chief Operating Officer

Mr. Sidney Taubenfeld R.Ph
Chief Operating Officer

Ms. Joy Willis
Director of Investor Relations

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$3,092,421

Shares Outstanding
60,302,222

Shares Short (% of Float)
()

Insider Ownership
47%